Product Details
Product Name:
Ravulizumab |
CAS No.:
1803171-55-2 |
Purity:
> 95% |
Supply Ability:
10g |
Release date:
2024/11/15 |
Product Introduction
Bioactivity
名稱 | Ravulizumab |
描述 | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. |
體外活性 | Binding to C5 with high affinity, Ravulizumab inhibits the formation of C5a and C5b, thereby preventing immune activation and hemolysis [1]. |
存儲(chǔ)條件 | store at low temperature | store at -80°C | Shipping with blue ice. |
關(guān)鍵字 | Ravulizumab | ALXN-1210 | ALXN 1210 |
相關(guān)產(chǎn)品 | EG01377 2HCl | Iptacopan hydrochloride | SB290157 trifluoroacetate | BCX 1470 hydrochloride | Complement C5-IN-1 | ADH-503 | CP-289 | Dexamethasone | CP-447697 | Complement factor D-IN-2 | Cyclosporin A | 3-Phenoxybenzaldehyde |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:150403-97-7
$138.00 / 5mg
-
CAS:154235-77-5
$30.00 / 1mL
-
CAS:8047-15-2
$52.00 / 500mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |